Distinguished in Cervical Cancer

Takayuki Ueno

Tokyo, JP 
Distinguished in Cervical Cancer
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Takayuki Ueno practices in Tokyo, Japan. Mr. Ueno is rated as a Distinguished expert by MediFind in the treatment of Cervical Cancer. His top areas of expertise are Breast Cancer, Cervical Cancer, Triple-Negative Breast Cancer, Mastectomy, and Salpingo-Oophorectomy.

His clinical research consists of co-authoring 154 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Ariake, 1358550, Japan
Chiba, Japan
Osaka, Japan
Kashiwa, Japan
Sendai, Japan
Chuo, 2608670, Japan
Kyotanabe, Japan
Sayo, 6795148, Japan
Mitaka, 1818611, Japan
Suita, Japan
Kyoto, Japan
Shinkawa, 1818611, Japan
Gifu-shi, Japan
Kawahara, 6068507, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3

154 Total Publications

Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.
Journal: Breast disease
Published: December 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ueno's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile